Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

SCG Cell Therapy and A*STAR Collaborate to Establish Joint Laboratories for Cellular Immunotherapies

NextEdge Admin

15 Apr 2024

3 min 17 sec

SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) have unveiled a groundbreaking collaboration to establish joint laboratories focused on cellular immunotherapies. With a combined funding of nearly S$30 million under Singapore’s Research, Innovation and Enterprise 2025 Plan (RIE2025), this initiative aims to propel the development of induced pluripotent stem cell (iPSC) technology toward producing innovative cell therapies meeting Good Manufacturing Practice (GMP) standards. Additionally, the partnership endeavors to cultivate a talent development program to nurture the next generation of experts in this domain, aligning with prevailing GMP and regulatory requisites.

Advancing healthcare necessitates not only research but also the transformation of laboratory breakthroughs into practical clinical solutions, which presents formidable challenges. These challenges encompass refining manufacturing processes, validating analytical methods, and integrating automation and digitalization for product stability and scalability assurance.

The joint laboratories, situated at SCG’s GMP facility and A*STAR’s research facility, capitalize on SCG’s specialized automated cell therapy manufacturing technologies and A*STAR’s proprietary monoclonal antibody assets, iPSC banks, and proficiency in process scaling and analytics. This collaborative effort synergizes the strengths of both entities, amalgamating resources from SCG Cell Therapy and A*STAR’s Bioprocessing Technology Institute (BTI) and Institute of Molecular and Cell Biology (IMCB) to drive innovative R&D toward GMP manufacturing standards. Moreover, it offers researchers immersion in a rigorously controlled GMP environment, facilitating the seamless transition from research to clinical application.

Christy Ma, Chief Strategy Officer of SCG Cell Therapy, expressed enthusiasm, highlighting the potential of cellular immunotherapies in revolutionizing regenerative medicine and underscoring the collaboration’s mission to provide accessible cell therapy treatment options. Prof Koh Boon Tong, Executive Director of A*STAR’s BTI, echoed this sentiment, emphasizing the acceleration of iPSC research translation into clinically viable therapies and bolstering Singapore’s global leadership in cell therapy innovation.

This partnership not only accelerates the translation of iPSC research into clinical therapies but also serves as a catalyst for nurturing future talent in this transformative field, ultimately advancing healthcare solutions to benefit patients worldwide.